Persistence of Symptoms After Improvement of Acute COVID-19
NCT04764773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 172
Last updated 2021-11-02
Summary
Coronavirus disease pandemic has been started in late 2019. Survivors of COVID-19 are significantly more likely to develop clinical sequelae three months after discharge from the hospital than those without COVID-19 infection. This is true not only for general and respiratory symptoms but also for cardiovascular and psychosocial symptoms. This suggests that these symptoms may indeed be the sequelae of recovery for COVID-19 survivors. So, we aimed to detect the prevalence and to evaluate the type of symptoms that could persist after the recovery from COVID19 infection in Sohag governorate, Egypt.
Conditions
- Corona Virus Infection
Interventions
- OTHER
-
No intervention
No intervention
Sponsors & Collaborators
-
Sohag University
lead OTHER
Principal Investigators
-
Noha Abdelrahman, assistant-lecturer · Sohag University
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-05-01
- Primary Completion
- 2021-02-28
- Completion
- 2021-03-31
Countries
- Egypt
Study Locations
More Related Trials
-
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
NCT04497649 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment
NCT04530422 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
NCT04773756 ·Status: COMPLETED ·Phase: PHASE4
-
Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19
NCT04447534 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
NCT04668469 ·Status: COMPLETED ·Phase: NA
-
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19
NCT04973462 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Favipiravir in Management of COVID-19
NCT04349241 ·Status: COMPLETED ·Phase: PHASE3
-
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
NCT04734873 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients
NCT04530370 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Sirolimus in COVID-19 Infection
NCT04461340 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT04779047 ·Status: UNKNOWN ·Phase: PHASE4
-
A Simple Approach to Treat COVID-19 Patients at Home.
NCT04794998 ·Status: COMPLETED
-
Surveillance of Individuals Following SARS-CoV-2 Infection
NCT04383444 ·Status: COMPLETED
-
Efficacy of Faviprevir in COVID-19 Treatment
NCT04351295 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hydroxychloroquine for Treatment of Non-Severe COVID-19
NCT04860284 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19
NCT04594343 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma Rich Antibodies From Recovered Patients From COVID19
NCT04348877 ·Status: UNKNOWN ·Phase: NA
-
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
NCT05195749 ·Status: TERMINATED ·Phase: PHASE2
-
Colchicine and Post-COVID-19 Pulmonary Fibrosis
NCT04818489 ·Status: UNKNOWN ·Phase: PHASE4
-
Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease
NCT04429867 ·Status: UNKNOWN ·Phase: PHASE4
-
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
NCT04334967 ·Status: SUSPENDED ·Phase: PHASE4
-
A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers
NCT04377646 ·Status: UNKNOWN ·Phase: PHASE3
-
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease
NCT04325893 ·Status: TERMINATED ·Phase: PHASE3
-
Sofosbuvir in Treatment of COVID 19
NCT04460443 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
NCT04491994 ·Status: COMPLETED ·Phase: PHASE3